SafeGuard Surgical

SafeGuard Surgical provides needed products that will ensure safer surgery for superior patient outcomes while reducing costs, preventing additional surgical interventions and reducing patient length of stay, but most importantly preventing mortality and morbidity which is much too common risk from surgery.

Our mission is a scalable and sustainable innovative global outreach to improve surgical outcomes in advanced surgical procedures adapting US ideas in underdeveloped and advancing outcomes in contemporary nations.

Our focus is attention specific to emerging markets, underserved and developing nations to prevent common leaks that have alarming mortality rates in the international community.

The United States is the world's largest medical device market and it shows no signs of slowing. The US medical device industry is valued at $159 billion in 2022 and is poised for steady growth, with global annual sales forecast to rise by over 5 percent a year and reach nearly US$800 billion by 2030  U.S. health care spending grew 9.7 percent in 2020, reaching $4.1 trillion or $12,530 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 19.7 percent.

We work with surgical oncologists, general surgeons, colon and rectal surgeons, and bariatric surgeons. Current products and services in development are: 

• Resorbable intraluminal stent graft to allow effective colonic anastomotic healing.
• Extraluminal resorbable graft to allow effective colonic anastomotic healing and stability.
• Anvil cap extension arms for superior stapling of end-to-end anastomosis.